OHSU

IRB #

IRB00009397

Title

A Phase Ib/II, Multicenter Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF Mutant Melanoma

Principal Investigator

Matthew Taylor

Study Purpose

To find the highest safe dose of LEE011 with LGX818 (the study drugs) in subjects with melanoma and to study the safety and effects of the study drugs.

Medical Condition(s)

Melanoma

Eligibility Criteria

1. Male or female 18 years or older
2. Locally advanced or metastatic melanoma with documented BRAF V600 mutation.
3. Tumor sample available for molecular testing
4. Other criteria also apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression, unacceptable side effects, or participant's decision to withdraw from the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Novartis Pharmaceutical Corporation

Recruitment End

02/27/2015

Compensation Provided

No


Go Back